Home  »  Company  »  Ind Swift Ltd  »  Quotes  »  Notes to Account
Enter the first few characters of Company and click 'Go'

Notes to Accounts of Ind Swift Ltd.

Mar 31, 2015

1. The Prefrence Shares shall rank for dividends in priority to equity Shares for time being. These shares shall be entitled to rank in priority to equity shares as regards repayment of Capital and arrears of dividend declared, but shall not be entitled to any further participation in profit or assets of the Company.

2. Term Loan from Banks & Financial Institutions are secured by way of first pari-passu charge over entire fixed assets of the company,second pari-passu charge over the entire current assets of the company,personal guarantee of Directors and by way of pledge of shares of promoters. Restructured Bill Discounting/Factoring facilities are secured by way of subservient charge over entire current assets of the company. Vehicles loans are secured by way of hypothecation of vehicles financed.

3.regarding regd. under The Micro Small and Medium Enterprises Development act 2006. Hence, the information required to be given in accordance with Section 22 of the said act is not ascertainable and not disclosed.

4. Total Cost of Quoted Investment is Rs. 4005.53 lacs(Market Value Rs.3016.16lacs) and Unquoted Investment is Rs. 506.80 lacs

5. The shares of Ind Swift Laboratories Ltd are pledged to Banks as per the sanctioned Corporate Debts Restructuring Scheme of Ind Swift Laboratories Ltd.

6. Ind Swift Laboratories Ltd, Essix Biosciences Ltd, Fortune India Construction Ltd and Mansa Print & Publishers Pvt. Ltd are Associates.

7. Fixed Deposits with banks are Rs.43.17 lacs (P/Y Rs. 225.73 lacs) out of which Rs. 43.11 lacs (P/Y Rs. 225.53 lacs) are Pledged as margin money with banks.

8. Balance with Banks includes Balance on account of unpaid dividend of Rs. 12.98 lacs(P/Y Rs. 17.56 lacs)

9. During the period the Company has Transferred a sum of Rs. 4.58 lacs to Investor Education and Protection Fund on account of Unclaimed dividend for Financial Year 2006-07 (P/Y Rs. 3.26 lacs)

10. In the opinion of the Board, the current assets,loans & advances shown in the Balance Sheet have a value of realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet and provision for all known and determined liabilities is adequate.

11. Expenses includes Rs.142.76lacs- (P/Y Rs. 36.96lacs) as expenses relating to previous years.

12. In view of losses, the managerial remuneration paid/provided is in excess of limit prescribed main schedule V of Companies Act 2013. However Company is in process of obtaining the approval from Central Government in this regard.

13. The previous year figures have been re-arranged and re-grouped wherever found necessary.

14. Contingent liabilities outstanding as on 31.03.2015 are as under:

a) Foreign Letter of Credit/Inland Letter of Credit/Bank Guarantee issued by Bankers:

(Rs.in Lacs)

Particulars 2014-15 2013-14

FLC /ILC 9.40 1630.91

BG 106.60 18.06

b) Arrears of Cumulative Dividend on cumulative Redeemable Preference Shares amounting to Rs. 56.80 Lacs Previous year (42.60Lacs).

c) In respect of Income Tax matters pending before appellate authorities/CIT (Appeals) which the Company expects to succeed, based on decisions of Tribunals/Courts. There is contingent liability amounting to Rs.578Lacs.

d) In respect of Sale Tax matters pending before appellate authorities/CIT (Appeals) which the Company expects to succeed, based on decisions of Tribunals/Courts. There is contingent liability amounting to Rs.590.64Lacs.

15. During the year the Company has changed the depreciation policy from straight line method to Useful Life method of depreciation as prescribed in Schedule II of the Companies Act, 2013. Due to this change in the method of depreciation, the reported period of depreciation is higher by Rs. 1252.66 lacs. However depreciation on fixed assets whose useful life is already exhausted as on 01.04.2014 amounting to Rs. 335.26 lacs has been debited to General Reserve Account. The Corresponding Deferred Tax Liability on such fixed assets amounting to Rs. 63.88 lacs has also been reversed and credited to General Reserve Account.

16. Trade Receivables include a sum of Rs. 63.39 Cr. Which is outstanding for a period of more than 3 years and are doubtful of recovery. However, no provision against the same has been made in the books of account as the management is hopeful of recovery of the same through constant follow up or by legal process as the management is contemplating to initiate legal action against such debtors.

17. Loss for the year has increased by Rs. 2238.75 lacs being the stocks written off by the company on account of expired/spoilage stocks of finished goods/raw material which was identified by the management during the financial year, being not realizable in normal course of business.

Further, the management has also identified stocks of finished goods/raw material worth Rs 39.44 Cr. as slow moving/non moving stocks which has not been written off during the financial year. However the value of such stock has been taken at realizable value.

18. At the end of the financial year the accumulated losses of the company are in excess of fifty percent of its net worth. During the financial year the company has also incurred cash losses.

19. R & D: Company is consistently undertaking Research & Development in new areas of Medicine. The R & D facility of the company is duly recognized by Deptt. of Science & Technology, Govt. of India. Company's team consisting of highly qualified scientists has proven their expertise in various areas of technology development. Expenses on Research phase are charged to Profit and Loss account and Expenses relating to development phase is recognised as an Intangible Asset only if it meets the recognition criteria as laid by AS 26 issued by institute of Chartered Accountant of India on Intangible Assets. These assets are amortised over the useful period of life starting from the year when the asset first meets the recognition criteria. Expenditure on R&D incurred by the Company during the Year is:

20. Segment Reporting

Primary Segment (Business Segments)

The Company operates mainly in the business segment of Pharmaceutical Products, and in the opinion of the management the inherent nature of activities in which it is engaged are governed by the same set of risks and reward. The Company has closed its operation in Dairy Division in the year 2013-14

21. The debts of the company including interest have been restructured by the corporate debt restructuring cell w.e.f 01.07.2012 under the aegis of Corporate Debt Restructuring Scheme. As per the approved scheme, restructured debts are now repayable over a period of eight and half years including moratorium period of 1-2years. The Debt Restructuring Scheme is not approved by Non CDR member Tata Capital Financial Services Ltd. However effect of reschedulement of loan has been incorporated in Balance Sheet as per corporate debt restructuring scheme except in case of Tata Capital Financial Services Ltd which has been taken as per their original sanctioned letter.

22. The fixed deposits of the company has been restructured by the Company Law Board vide its order dated 30.09.2013 in view of petition CP No, 27.02.2013 filed by the company. As per the scheme approved by the Company Law Board the fixed deposits are now repayable over a period of one to five years from the date of maturity. The effect of rechedulement of fixed deposits has been incorporated in Balance Sheet as per the approved scheme.

23. In view of the financial crisis being faced by the company, Company is finding difficulties in making payment of dues to the banks/ financial institutions i.e. interest and installments in terms of the CDR package approved by CDR EG vide letter dated 27.12.2012 Hence, accounts pertaining to Cash Credit (CC), Term Loans (TL), Working Capital Term Loans (WCTL), Funded Interest Term Loans (FITL) with some banks have been declared as NPAs by respective banks due to non-payment of dues on time. Such banks have not charged interest on CC,TL, WCTL & FITL accounts post such accounts becoming NPAs. The accrued liability on account of the same amounting to Rs. 85.48 Cr. (Previous Year 37.10 Cr.) has not been provided in the books of accounts.

24. Since the Company is incurring losses and there is no virtual certainty regarding availability of any future taxable profits in coming financial years, as such in accordance with AS-22 (Accounting for Taxes) the Company has not recognized Deferred Tax Asset .

25. Due to Suspension of activities at Unit I, and II since March 2014 and suspension of activity at Dairy Unit since Aug.2013, There are indication which suggest impairment as per AS-28 issued by ICAI in the value of fixed assets being plant & machinery and other fixed assets of the Company. The management is in the process of getting an impairment study done and this financial impact of the impairment loss, if any, will be accounted for at the material time, when the impairment study will be completed.

26. Balance of Debtors,Creditors and Loan & Advances are subject to Confirmation.

27. Related Party Disclosure

(a) List of related parties & their relationship - As per annexure- 'A'

(b) Related party transactions. - As per annexure- 'B'

RELATED PARTY DISCLOSURES Annexure - '43 A'

LIST OF RELATED PARTIES AND RELATIONSHIPS

(A) ASSOCIATES

1. ESSIX BIOSCIENCES LIMITED.

2. IND SWIFT LABORATORIES LIMITED.

3. MANSA PRINT & PUBLISHERS LIMITED.

4. FORTUNE INDIA CONSTRUCTION LIMITED.

5 DASHMESH MEDICARE PVT LIMITED.

6. 3M ADVERTISING & PUBLISHERS LIMITED.

7. SWIFT FUNDAMENTAL RESEARCH & EDUCATION SOCIETY.

8. HALCYON LIFE SCIENCES PVT. LIMITED.

9. PUNJAB RENEWABLE ENERGY PVT LIMITED.

10. B. M. COSMED PVT. LIMITED.

11. HAKIM FARAYAND CHEMI CO. (IRAN)

12. AKJ PORTFOLIOS PVT. LIMITED.

13. NRM PORTFOLIOS PVT LIMITED.

14. SRM PORTFOLIOS PVT LIMITED.

15. GM PORTFOLIOS PVT LIMITED.

16. VRM PORTFOLIOS PVT LIMITED.

17. VKM PORTPOLIOS PVT LIMITED.

(B) KEY MANAGEMENT PERSONNEL

1. MR. S.R. MEHTA, CHAIRMAN DIRECTORS

2. DR. G. MUNJAL, MANAGING DIRECTOR & CEO

3. DR. V.R.MEHTA, JT. MANAGING DIRECTOR

4. MR.RAMAN K. SOOD, COMPANY SECRETARY

5. MR. ARUN K. SETH, G.M. (F&A) designated as CFO










Mar 31, 2014

1. Leases:

Finance lease, which effectively transfer to the company all the risks and benefits incidental to ownership of the leased item, are capitalized at the lower of the fair value and present value of the minimum lease payments at the inception of the lease term and disclosed as leased assets. Lease payments are apportioned between the finance charges and reduction of the lease liability based on the implicit rate of return. Fi- nance charges are charged as expenses in the profit and loss account.

2. Accounting policies not specifically referred to are consistent with generally accepted accounting principles.

3. The Prefrence Shares shall rank for dividends in priority to equity Shares for time being. These shares shall be entitled to rank in priority to equity shares as regards repayment of Capital and arrears of dividend declared, but shall not be entitled to any further participation in profit or assets of the Company.

4. During the year the company has alloted 4168571 equity shares of Rs. 2/- each @ a preimum of Rs. 15.50 per share to promoters and promoter group compines as per the approved CDR Scheme.

5. Term Loan from Banks & Financial Institutions are secured by way of first pari-passu charge over entire fixed assets of the company,second pari-passu charge over the entire current assets of the company,personal guarantee of Directors and by way of pledge of shares of promoters. Restructured Bill Discounting/Factoring facilities are secured by way of subservient charge over entire current assets of the company. Vehicles loans are secured by way of hypothecation of vehicles financed.

6. The Company has not received any information from its suppliers regarding regd. under The Micro Small and Medium Enterprises Development act 2006. Hence, the information required to be given in accordance with Section 22 of the said act is not ascertainable and not disclosed.

7. Total Cost of Quoted Investment is Rs. 4005.53lacs(Market Value Rs.3671.64 lacs) and Unquoted Investment is Rs. 513.35 lacs

8. The shares of Ind Swift Laboratories Ltd are pledged to Banks as per the sanctioned Corporate Debts Restructuring Scheme of Ind Swift Laboratories Ltd.

9. Ind Swift Laboratories Ltd, Essix Biosciences Ltd, Fortune India Construction Ltd and Mansa Print & Publishers Pvt. Ltd are Associates.

10. Fixed Deposits with banks are Rs. 225.73 lacs (P/Y Rs. 949.24 lacs) out of which Rs.225.53 lacs (P/Y Rs. 948.11 lacs) are Pledged as '' margin money with banks.

11. Balance with Banks includes Balance on account of unpaid dividend of Rs. 17.56 lacs (P/Y Rs. 20.82 lacs)

12. During the period the Company has Transferred a sum of Rs. 3.26 lacs to Investor Education and Protection Fund on account of Unclaimed dividend for Financial Year 2005-06 (P/Y Rs. 3.24 lacs)

13. In the opinion of the Board, the current assets,loans & advances shown in the Balance Sheet have a value of realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet and provision for all known and determined liabilities is adequate.

14. Expenses includes Rs. 36.96 lacs (P/Y Rs. 32.08 lacs) as expenses relating to previous years.

15. In view of losses, the managerial remuneration paid/provided is in excess of limit prescribed main schedule XIV of Companies Act 1956. However Company is in process of obtaining the approval from Central Government in this regard.

During the year, the Company has undertaken a review of all fixed assets in line with the requirement of AS-28 on "Impairment of

16. Assets" issued by the Institute of Chartered Accountants of India. Based on such review, no provision for impairment is required to be recognized for the year.

17. The previous year figures have been re-arranged and re-grouped wherever found necessary.

18. Contingent liabilities outstanding as on 31.03.2014 are as under:

a) Foreign Letter of Credit/Inland Letter of Credit/Bank Guarantee issued by Bankers:

(Rs.in Lacs)

Particulars 2013-14 2012-13

FLC /ILC 1630.91 2310.91

BG 18.06 822.69

b) Arrears of Cumulative Dividend on cumulative Redeemable Preference Shares amounting to Rs. 42.60 Lacs Previous year (28.40Lacs).

c) In respect of Income Tax matters pending before appellate authorities/CIT (Appeals) which the Company expects to succeed, based on decisions of Tribunals/Courts. There is contingent liability amounting to Rs. 578 Lacs.

d) In respect of Sale Tax matters pending before appellate authorities/CIT (Appeals) which the Company expects to succeed, based on decisions of Tribunals/Courts. There is contingent liability amounting to Rs. 590.64 Lacs.

19. During the year, the Company has received a sum of Rs. 668.10 Lacs as promoters contributions towards Share Application Money in compliance with the term and conditions of CDR Package.

10. R & D: Company is consistently undertaking Research & Development in new areas of Medicine. The R & D facility of the company is duly recognized by Deptt. of Science & Technology, Govt. of India. Company''s team consisting of highly qualified scientists has proven their expertise in various areas of technology development. Expenses on Research phase are charged to Profit and Loss account and

11. The debts of the company including interest have been restructured by the corporate debt restructuring cell w.e.f 01.07.2012 under the aegis of Corporate Debt Restructuring Scheme. As per the approved scheme, restructured debts are now repayable over a pe- riod of eight and half years including moratorium period of 1-2years. The Debt Restructuring Scheme is not approved by Non CDR member Tata Capital Financial Services Ltd. However effect of Reschedulment of loan has been incorporated in Balance Sheet as per corporate debt restructuring scheme except in case of Tata Capital Financial Services Ltd which has been taken as per their original sanctioned letter.

12. The fixed deposits of the company has been restructured by the Company Law Board vide its order dated 30.09.2013 in view of petition CP No, 27.02.2013 filed by the company. As per the scheme approved by the Company Law Board the fixed deposits are now repayable over a period of one to five years from the date of maturity. The effect of reschedulement of fixed deposits has been incorporated in Balance Sheet as per the approved scheme.

13. During the year some banks have not charged interest for full year due to sub standard account on cash credit, working capital Term Loan, Term Loan and Funded interest Term Loan accounts. The accrued liability on account of the same amounting to Rs. 3709.75 lacs has not been provided in books of accounts.

14. Remittance in Foreign Currency on Account of Dividend:

The Company has paid dividend in respect of shares held by Non-Residents. Where the amount is also credited to Non-Resident External Account.

15. The current accounting period is for Twelve months from 01.04.2013 to 31.03.2014 and previous accounting period was for nine months from 01.07.2012 to 31.03.2013, hence the figures for the current period are not comparable with the previous period.


Mar 31, 2013

1. The Prefrence Shares shall rank for dividends in priority to equity Shares for time being. These shares shall be entitled to rank in priority to equity shares as regards repayment of Capital and arrears of dividend declared, but shall not be entitled to any further participation in profit or assets of the Company

2. Term Loan from Banks & Financial Institutions are secured by way of first pari-passu charge over entire fixed assets of the company,second pari-passu charge over the entire current assets of the company,personal guarantee of Directors and by way of pledge of shares of promoters. Restructured Bill Discounting/Factoring facilities aresecured by way of subservient charge over entire current assets of the company. Vehicles loans are secured byway of hypothecation of vehicles financed.

3. Fixed Deposits with banks are Rs. 949.24 lacs (P/Y Rs. 1976.93 lacs) out of which Rs.948.11 lacs (P/Y Rs. 1758.42 lacs) are Pledged as margin money with banks.

4. Balance with Banks includes Balance on account of unpaid dividend of Rs. 20.82 lacs(P/Y Rs. 24.16lacs)

5. During the period the Company has transferred a sum of Rs. 3.24 lacs to Investor Education and Protection Fund on account of Unclaimed dividend for Financial Year 2004-05 (P/Y Rs. 2.65 lacs)

6. In the opinion of the Board, the current assets,loans & advances shown in the Balance Sheet have a value of realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet and provision for all known and determined liabilities is adequate.

7. Expenses includes Rs. 32.08Lacs (P/Y Rs. 18.29Lacs) as expenses relating to previous years.

8. In view of losses, the managerial remuneration paid/provided is in excess of limit prescribed under schedule XIV of Companies Act 1956. However Company is in process of obtaining the approval from Central Government in this regard. During the year, the Company has undertaken a review of all fixed assets in line with the requirement of AS-28 on "Impairment of Assets" issued by the Institute of Chartered Accountants of India. Based on such review, no provision for impairment is required to be recognized for the year.

9. The previous year figures have been re-arranged and re-grouped wherever found necessary.

10. Contingent liabilities outstanding as on 31.03.2013 are as under:

a) Foreign Letter of Credit/Inland Letter of Credit/Bank Guarantee issued by Bankers:

(Rs.in Lacs)

Particulars 2012-13 2011-12

FLC /ILC 2310.91 21427.49

BG 822.69 1404.25

b) Arrears of Cumulative Dividend on cumulative Redeemable Preference Shares amounting to Rs.28.40 Lacs Previous year (14.20Lacs).

c) In respect of Income Tax matters pending before appellate authorities/CIT (Appeals) which the Company expects to succeed, based on decisions of Tribunals/Courts. There is contingent liability amounting to Rs. 578 Lacs.

d) In respect of Sale Tax matters pending before appellate authorities/CIT (Appeals) which the Company expects to succeed, based on decisions of Tribunals/Courts. There is contingent liability amounting to Rs. 590.64 Lacs.

11. During the period, the Company has received a sum of Rs. 729.50 Lacs as promoters contributions towards Share Application Money in compliance with the term and conditions of CDR Package.

12. Segment Reporting

Primary Segment (Business Segments)

The Company operates mainly in the business segment of Pharmaceutical Products, and in the opinion of the management the inherent nature of activities in which it is engaged are governed by the same set of risks and reward. The company has also diversified into Dairy segment in addition to the Pharmaceuticals. As the revenue from the dairy segment is less than 10% of total income of the company, hence separate segment reporting has not been given.

13. The debts of the company including interest have been restructured by the corporate debt restructuring cell w.e.f 01.07.2012 under the aegis of Corporate Debt Restructuring Scheme. As per the approved scheme, restructured debts are now repayable over a period of eight and half years including moratorium period of 1-2years. The Debt Restructuring Scheme is pending for approval from Non CDR members IFCI and Tata Capital Financial Services Ltd, however effect of Reschedulment of loan has been incorporated in Balance Sheet as per corporate debt restructuring scheme subject to their approval.

14. Remittance in Foreign Currency on Account of Dividend:

The Company has paid dividend in respect of shares held by Non-Residents. Where the amount is also credited to Non-Resident External Account.

15. Related Party Disclosure

(a) List of related parties & their relationship - As per annexure- 'A' (b) Related party transactions. - As per annexure- 'B'

16. The current accounting period is for nine months from 01.07.2012 to 31.03.2013 and previous accounting period was for fifteen months from 01.04.2011 to 30.06.2012, hence the figures for the current period are not comparable with the previous period

RELATED PARTY DISCLOSURES

LIST OF RELATED PARTIES AND RELATIONSHIPS

S.NO. RELATIONSHIP NAME OF PARTY

(A) ASSOCIATES 1. ESSIX BIOSCIENCES LTD. 2. IND SWIFT LABORATORIES LIMITED 3. MANSA PRINT & PUBLISHERS LTD. 4. FORTUNE INDIA CONSTRUCTION LTD 5. DASHMESH MEDICARE PVT LTD. 6. 3M ADVERTISING & PUBLISHERS LTD 7. SWIFT FUNDAMENTAL RESEARCH & EDUCATION SOCIETY

(B) KEY MANAGEMENT PERSONNEL 1. MR. S.R. MEHTA - DIRECTORS 2. DR. G. MUNJAL 3. DR. V.R.MEHTA




Mar 31, 2010

1. The previous year figures have been re-arranged and re-grouped wherever necessary.

2. The Company has sent letter of balance confirmation to all the parties but only a few have re- sponded so far. So the balance in the party accounts whether in debit or in credit are subject to reconciliation.

3. Land Amounting to Rs. 4.43Lacs continues to be in the name of Mukur Pharmaceutical Co. Pvt. Ltd.

4. The Company is a manufacturing company, so the information pursuant to the provisions of paragraph 3 & 4 of part II of schedule VI to the Companies Act, 1956 is as under: -

a) (i) Licensed Capacity - N.A.

(ii) Installed Capacity - (As on 31.03.2010)

- (As certified by the Management)

5. Fixed deposits with banks are Rs. 179826452/- (P/Y Rs.81988543/-) out of which Rs.90825353/- ( P/Y- Rs.62444895/-) are pledged as margin money with banks.

6. Expenses includes Rs.875994/- (P/Y Rs.3038831/-) as expenses relating to previous years.

7 . Income includes Rs.Nil (P/Y Rs.999118/-) as income relating to previous years.

8. Depreciation on assets has been provided for the entire accounting year on straight line method at the rates prescribed by Schedule XIV of the Companies Act, 1956. Depreciation in respect of additions to assets has been charged on prorata basis with reference to the period of use of such assets.

9. Contingent liabilities outstanding as on 31.03.2010 are as under:

a) Foreign Letter of Credit/Inland Letter of Credit/Bank Guarantee issued by Bankers:

Particulars 2009-10 2008-09

(Rs.in Lacs)

FLC 679.00 351.39

ILC 11762.58 9055.31

BG 96.89 68.19

b) Corporate Guarantee on behalf of Ind Swift Laboratories Ltd of which company is the share- holder amounting to Rs.5000/- Lacs ( Previous Year Rs.1752/- Lacs) based on outstanding balances at the year end.

c) In respect of Income Tax matters pending before appellate authorities/CIT (Appeals) which the Company expects to succeed, based on decisions of Tribunals/Courts. There is contingent liability amounting to Rs. 5.56 crores.

10. Company has further invested Rs. 37500000/- in M/s Ind Swift Labs Ltd for which 30,00,000 of Zero coupon optionally convertible warrants from the Promoters Group Company have been received.

11. a) The Company has raised a sum of Rs. 24.20 Crores only (Twenty Four Crores twenty lacs only) as advance against Share Capital from private corporate Bodies, for which the company is in pro- cess of issuing Preference Shares.

b) The Company has received a sum of Rs. 2.5 crores (Rs. Two Crores Five lacs only) from M/s Essix Biosciences Ltd. as application money (25% of the issue price) for issue of 4000000 Zero Coupon Convertible Warrants (ZCCB) issued for Rs. 25/- per warrant.

12. The Investment in M/s Mansa Print & Publishers Ltd as on 31.03.2010 is Rs.1334500/-.

13. The company has introduced new product ranges like Anich-3,Clarie Dry Syrup,Cirrholiv Dry Syrup, PM Care Gold, Expodox-CV 100, Glypar-lmg, Glypar M1ER, Glypar 2mg etc. during the year 2009-2010. The company has also substantially increased the number of head quarters in the states where it was working on a smaller scale. Expenses relating to the introduction & establish- ment of New Products Head Quarters have enduring beneficial effect beyond the year in which these are incurred. Such expenses are clubbed under the head Seed Marketing Expenses to be amortized in subsequent five equal annual installments.

The Depreciation and Misc. exp. w/off related to Research & development are clubbed under respective heads in profit & loss account.

14. Total amount of term loans/installments of term loans repayable during twelve months following 31.03.2010 is Rs 5964.71 Lacs (Previous year Rs.4738.42 Lacs) and public deposits amounting to Rs. 482.50 Lacs (P/Y Rs.789.25 Lacs).

15. Loans and Advances due from officers of the company is Rs.3.72Lacs (Previous Year Rs.5.51Lacs) Maximum amount outstanding during the year was Rs.5.82 Lacs (Previous Year Rs.7.24 Lacs).

16. In the opinion of the Board, the current assets, loans & advances shown in the Balance Sheet have a value of realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet and provision for all known and determined liabilities is adequate.

17. Some of the suppliers of materials have been identified as Small Scale Industrial Undertakings on the basis of the information available with the company. However some of these parties has an outstanding credit balance for more than 30days as on 31.03.2010

18. There were no lease obligations outstanding during the year and consequently no lease rentals were payable. There are no unexpired lease obligations as at the year end.

19. In the opinion of the management, the company is mainly engaged in the business of Pharma- ceuticals. All activities of the company revolve around the fnain business and as such there are no separate reportable segments. The company caters mainly to the needs of the domestic market. The export turnover being less than 10% of the total turnover, there are no reportable geographi- cal segments.

20. Due to occurrence of fire at Parwanoo Plant there was loss of stocks and assets thus the company has lodged an insurance claim of Rs. 7.11 Crores with united India Assurance Company Ltd. and the same is pending as on 31.03.2010

21. Company has taken a Defined Contribution Plan from Life Insurance Corporation of India which takes care its liability towards Gratuity entirely. As per Accounting Standard 15 on "Employee Benefits the disclosure is given below.

i) Employers Contribution to PF Rs. 11361502/-

ii) Contribution to Gratuity Rs. 3107710/-

22. Intangible Assets :

a) Product Technology acquired by the company is recognized as an intangible asset and is amortised over its useful life of 5 years.

23. During the year, the Company has undertaken a review of all fixed assets in line with the require- ment of AS-28 on "Impairment of Assets" issued by the Institute of Chartered Accountants of India. Based on such review, no provision for impairment is required to be recognized for the year.

24. The figures have been rounded to the nearest rupee.

 
Subscribe now to get personal finance updates in your inbox!